BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,216,690 | -16.2% | 267,617 | +0.5% | 0.01% | -13.3% |
| Q2 2023 | $21,741,090 | +2.2% | 266,337 | -7.1% | 0.02% | 0.0% |
| Q1 2023 | $21,267,305 | -8.7% | 286,660 | +2.0% | 0.02% | -16.7% |
| Q4 2022 | $23,289,943 | +18.6% | 281,008 | +306.3% | 0.02% | +12.5% |
| Q3 2022 | $19,640,000 | -32.1% | 69,156 | -17.1% | 0.02% | -23.8% |
| Q2 2022 | $28,919,000 | -22.0% | 83,426 | -2.6% | 0.02% | -8.7% |
| Q1 2022 | $37,076,000 | -42.3% | 85,616 | -31.1% | 0.02% | -39.5% |
| Q4 2021 | $64,240,000 | -1.7% | 124,172 | -7.9% | 0.04% | -11.6% |
| Q3 2021 | $65,334,000 | -15.9% | 134,831 | -21.9% | 0.04% | -14.0% |
| Q2 2021 | $77,732,000 | +17.6% | 172,639 | -0.2% | 0.05% | +6.4% |
| Q1 2021 | $66,098,000 | +78.6% | 173,062 | +48.5% | 0.05% | +74.1% |
| Q4 2020 | $37,014,000 | +28.4% | 116,561 | +0.2% | 0.03% | +12.5% |
| Q3 2020 | $28,822,000 | -9.0% | 116,343 | -3.0% | 0.02% | -14.3% |
| Q2 2020 | $31,659,000 | +42.1% | 119,886 | +2.1% | 0.03% | +12.0% |
| Q1 2020 | $22,274,000 | -39.0% | 117,464 | -29.4% | 0.02% | -16.7% |
| Q4 2019 | $36,507,000 | +12.3% | 166,314 | +0.1% | 0.03% | +3.4% |
| Q3 2019 | $32,503,000 | -7.7% | 166,114 | -1.7% | 0.03% | -9.4% |
| Q2 2019 | $35,219,000 | +5.7% | 168,926 | +0.6% | 0.03% | +3.2% |
| Q1 2019 | $33,333,000 | +38.0% | 167,883 | +0.6% | 0.03% | +19.2% |
| Q4 2018 | $24,160,000 | -29.1% | 166,943 | +0.0% | 0.03% | -13.3% |
| Q3 2018 | $34,062,000 | +37.1% | 166,884 | -0.6% | 0.03% | +30.4% |
| Q2 2018 | $24,846,000 | -25.9% | 167,933 | -24.3% | 0.02% | -28.1% |
| Q1 2018 | $33,513,000 | +30.3% | 221,887 | +11.8% | 0.03% | +33.3% |
| Q4 2017 | $25,720,000 | -9.7% | 198,533 | -15.7% | 0.02% | -14.3% |
| Q3 2017 | $28,476,000 | +4.6% | 235,559 | +1.7% | 0.03% | +3.7% |
| Q2 2017 | $27,222,000 | +74.6% | 231,680 | +51.0% | 0.03% | +42.1% |
| Q1 2017 | $15,592,000 | +1.3% | 153,397 | +2.5% | 0.02% | -5.0% |
| Q4 2016 | $15,393,000 | -5.4% | 149,689 | +0.7% | 0.02% | -4.8% |
| Q3 2016 | $16,277,000 | +1.3% | 148,648 | +4.3% | 0.02% | -4.5% |
| Q2 2016 | $16,074,000 | +36.0% | 142,542 | +14.0% | 0.02% | +29.4% |
| Q1 2016 | $11,823,000 | +13.0% | 125,082 | +7.6% | 0.02% | +6.2% |
| Q4 2015 | $10,466,000 | -1.8% | 116,293 | +0.9% | 0.02% | -5.9% |
| Q3 2015 | $10,656,000 | +2.9% | 115,250 | +9.6% | 0.02% | +13.3% |
| Q2 2015 | $10,354,000 | +2.7% | 105,151 | +4.5% | 0.02% | 0.0% |
| Q1 2015 | $10,086,000 | +8.1% | 100,575 | -0.4% | 0.02% | +7.1% |
| Q4 2014 | $9,331,000 | – | 100,983 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |